Advertisement
Research Article

Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer

  • Kelly Coffey,

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Timothy J. Blackburn,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Susan Cook,

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Bernard T. Golding,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Roger J. Griffin,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Ian R. Hardcastle,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Lorraine Hewitt,

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Kety Huberman,

    Affiliation: OSI Pharmaceuticals, Inc, Farmingdale, New York, United States of America

    X
  • Hesta V. McNeill,

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • David R. Newell,

    Affiliation: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Celine Roche,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Claudia A. Ryan-Munden,

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Anna Watson,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Craig N. Robson mail

    c.n.robson@ncl.ac.uk

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Published: October 08, 2012
  • DOI: 10.1371/journal.pone.0045539

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.